Journal of Hepatology

Article	Citations
A step forward to predict the risk of post-hepatectomy portal hypertension	2237
Further on ammonia concentration, -clearance, -removal, and -production	1332
Editorial Board	993
Let’s unite Hepatology! Become an EASL member today and discover your benefits	951
Reply to: “We need to talk about #livertwitter”	881
Fritz von Weizsäcker 1960–2019: An exceptional physician-scientist	819
Editorial Board	664
Reply to: “Reassessing the causal relationship between liver diseases and cardiovascular outcomes” and “From liver to heart: Enhancing the understanding of cardiovascular outcomes in the UK Biobank”	394
Get ready for the EASL Studio season 6!	284
Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody	283
Viral Hepatitis Elimination 2022 – Don’t miss this special conference in Brussels & register with early fees by 4 January!	252
Apply now for the EASL School 2022	249
Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease	248
From the Editor’s Desk...	239
Reply to: “Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis”	231
From the Editor’s Desk...	219
The protective association of HLA-B∗52:01, HLA-C∗12:02, and DQB1∗06:01 alleles with severe acute hepatitis of unknown origin in Japanese children	216
Improved assessment of donor liver steatosis using Banff consensus recommendations and deep learning algorithms	213
The space of Mall confirmed in humans: A response to “Portal venous branches as an anatomic railroad for a gut-bile duct axis”	212
Submit your late-breaker abstract for the EASL Congress 2024 between 27 March - 10 April	211
Visit EASL Campus & discover 4,100 + resources on hepatology & liver-related research	205
Defining the prognosis of critically ill patients with alcohol-related liver disease	200
Rising clinical and economic burden among hepatitis D patients who attended Spanish hospitals	200
Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis	188
Reply to: “TIPS and liver transplantation should always be discussed together”	181

Join the EASL Community & enjoy reduced fees to all EASL events	178
Transient elastography in chronic liver disease: Beware of the cut-offs!	176
Combination of crafity score with alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma	173
Human duodenal submucosal glands contain a defined stem/progenitor subpopulation with liver-specific regenerative potential	172
Combination immunotherapy for hepatocellular carcinoma	170
Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease	164
Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis	162
Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD	161
A pilot study to improve the uptake of hepatocellular carcinoma surveillance	159
Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease	159
Become an EASL Member & join the global liver community, or renew your membership	159
Prevalence and incidence of delta hepatitis in HIV-HBV coinfected patients in the Dat’AIDS cohort	157
Estimating the economic value allocation of the social surplus generated by the utilization of second-generation direct-acting antivirals for hepatitis C in the United States, 2015–2019	153
SIRIUS project: sensing probe exploring liver fibrosis in Slovakia	150
Global burden of common cancers attributable to metabolic risks from 1990 to 2019	150
Opt-out testing for hepatitis B and C infections in adults attending the emergency department of a London Hospital	149
Policy and implementation needs for hepatitis B birth dose in the WHO African region: a survey of national program managers	148
Late presentation of chronic hepatitis C for care in Georgia: data from the national hepatitis C elimination program, 2016–2021	148
The impact of hepatitis D virus infection on health-related quality of life and fatigue in patients untreated for HDV: descriptive results from a cross-sectional study across Italy, Germany, Spain and	148
One step closer to the goal: mobile InfoHep centre offering detection, protection, prevention and treatment/linkage- to care services in Croatian penalty institutions	144
Influence of language barrier and cultural differences in hepatitis B disease knowledge in the chinese community of Barcelona	144
Automation of hepatitis C screening through electronic health record algorithm	141
Hepatitis C seroconversion rates among individuals with repeated testing-Georgia, 2017–2021	138
Acceptance and feasibility of hepatitis C screening by assisted self-testing in high-risk and general population: a randomized clinical trial	136
FIB-4 outperforms other serum non-invasive fibrosis tests in metabolic associated fatty liver disease	134
Glycemic control as a modifiable and independent risk factor for the development of liver, biliary tract and pancreatic cancer: a territory-wide study of 273,421 patients with diabetes mellitus	132
Results of the Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) study 1.1 on the reproducibility and repeatability of shear-wave and transient elastography in non-alcoholic fatty liver dise	130
Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm	129
Epidemiology and characteristics of hepatocellular carcinoma in France: results of the first 2000 patients in real-life situations from the French prospective chief cohort	128
Study of hepatitis delta virus replication markers in anti-HBc positive patients with chronic hepatitis C	128
Genomic characteristics of hepatocellular carcinoma patients with response to sorafenib	127
Incidence of hepatitis D virus super-infection in HBsAg positive patients (The Inci-D cohort study)	127
Significant heterogeneity in long-term risks of cirrhosis or hepatocellular carcinoma among a national cohort of U.S. veterans with non-cirrhotic, treatment naïve chronic hepatitis B in the immune tol	125
Bisphosphonate-loaded nanogels attentuate liver fibrosis by repolarization of M2-type macrophages	125
Estimating the residual risk of hepatitis B mother-to-child transmission in The Gambia, 30 years after HBV vaccine implementation	124
Fragility index of positive phase 2 and 3 randomized clinical trials of treatment of hepatocellular carcinoma (2002–2022)	124
Performance of the Steatosis-Associated Fibrosis Estimator (SAFE) to predict F2 fibrosis and higher in a cohort of South Korean patients with non-alcoholic fatty liver disease (NAFLD)	124
Experimental fibrosis alters matrix-bound vesicles cargo that do not revert after histologic recovery	124
Using qFibrosis analysis to predict disease and survival outcome of patients with hepatocellular carcinoma after curative treatment	122
Contrasting immune fingerprints of chronic hepatitis B Virus infection in adults from South Africa and the United Kingdom	122
Effectiveness and safety of conversion surgery for patients with initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitors: a real-world study	121
Hepatocyte senescence is linked with extrahepatic organ injury, failure of regeneration and mortality in patients with acute indeterminate hepatitis	117
Identification and external validation of the optimal ALT thresholds for ruling in significant histologic disease in chronic hepatitis B	114
Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study	113
Imaging of fibrosis in metabolic associated liver disease by a radiolabeled affibody targeting PDGFRB	113
Perturbation of rhythmicity of the circadian clock-oscillator in hepatic stellate cells is associated with liver fibrosis	108
Incidence and risk factors of esophagogastric varices bleeding in patients with advanced hepatocellular carcinoma treated with lenvatinib	106
Risk stratification for early recurrence after resection in patients with intermediate stage hepatocellular carcinoma	105
Development of a high precision liver biopsy method to improve the accuracy of fibrosis staging and collagen profiling	105
Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction	105

Outcomes between surgical resection and transarterial chemoembolization in patients with multifocal BCLC-A and Child-Pugh B	104
Long-term outcome following liver transplantation for patients with acute on chronic liver failure grade 3 (ACLF-3): a retrospective matched-controlled study	104
The protective effect of time-caloric restriction in liver fibrosis induced by nitrosamines in rat model	104
Liver complications in greek patients with sickle cell disease: a multicenter retrospective analysis from eight thalassemia and sickle cell units across Greece	104
Stability of Hepatitis B virus RNA in plasma and serum under various storage conditions	103
Quantitative digital pathology of 3D human NASH models establish continuous scores to evaluate the antifibrotic effects of Selonsertib, Firsocostat and Resmetiron	102
Addressing the heterogeneity of fibrosis in liver biopsy specimens with qFibrosis – a new paradigm for an old problem	102
Performance of a p-SWE method implemented on a new ultrasound system for predicting advanced liver fibrosis	100
Sequential systemic treatment in patients with hepatocellular carcinoma: real-world data in the era of immune checkpoint inhibition	99
Exploring gender-related differences in liver fibrosis and regeneration through a new experimental carbon tetrachloride protocol in mice	99
Epidemiological landscape and clinical spectrum of chronic hepatitis B in East Africa	97
Inhibition of tumour progression locus 2 (TPL2) halts the progression of liver fibrosis in a stringent long term choline deficient high-fat diet (CdHFD) rat model	96
Multispectral imaging analysis of liver biopsies from patients with non-alcoholic steatohepatitis reveals enrichment of pathogenic macrophage phenotypes associated with disease progression	95
Diabetes, but not prediabetes, is associated with significant liver fibrosis	94
Clinical impact of relative dose intensity over the first four weeks in cabozantinib therapy for unresectable hepatocellular carcinoma	94
Aspirin use and risk of hepatocellular carcinoma and gastrointestinal bleeding in patients with HBV-related cirrhosis: a landmark analysis	94
Outcomes of early vs late treatment initiation in solid organ transplantation from HCV NAT+ donors to HCV-uninfected recipients: results from the HCV-TARGET study	93
Multiplexed digital spatial protein profiling reveals potential non-invasive biomarkers to predict advanced fibrosis	93
Diagnostic efficacy of Mac-2 binding protein glycosylation isomer for predicting liver fibrosis in patients with metabolic associated fatty liver disease	93
Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease	92
Causes of death by fibrosis stage in 959 biopsy-proven NAFLD patients	91
Deep dive analysis into the screening failure reasons: combined data from multiple therapeutic clinical trials including more than 5000 patients (in collaboration with NAIL-NIT consortium)	91
LncRNA XR_592974.2 and circRNA _2599 regulated hypoxic stress response in hepatic stellate cells by targeting the miRNA-145/JMY/ P53 pathway	91
Eliminating viral hepatitis one island at a time-the Hainan experience	91
Use of the enhanced liver fibrosis test to risk stratify patients in the intelligent liver function test pathway: ruling out cirrhosis and advanced fibrosis	90
A risk prediction model for hepatocellular carcinoma for non-alcoholic fatty liver disease without cirrhosis	90
Association between consumption of ultra-processed foods and non-alcoholic fatty liver disease in the Framingham heart study	90
The comparisons of clinical relapse timing and severity after cessation of prophylactic nucleos (t)ide analogue between chronic hepatitis B patients with lymphoma receiving chemotherapy with and witho	90
Prevalence and predictors of HDV viremia in anti-HDV positive patients of the HEllenic multicenter ReAl-life CLInical Study (HERACLIS-HDV)	90
A history of bariatric surgery is independently associated with a younger age at onset of severe alcoholic hepatitis	89
MELD-sarcopenia and clinically significant portal hypertension as independent risk factors in the evolution of liver cirrhosis	89
A novel nomogram for predicting HBeAg clearance in HBeAg-positive chronic hepatitis B patients after nucleos (t)ide analogues treatment	89
Suppression of the pituitary-adrenal axis in stable outpatients with advanced chronic liver disease increases with disease severity and may be linked to systemic inflammation and bile acids	89
Bacterial translocation has an early onset in cirrhosis and induces a selective inflammatory response	87
A novel autophagy inducer attenuated non-alcoholic steatohepatitis by regulating the adneylate cyclase 6 in hepatocytes	87
Infections are common in patients with early alcohol-related liver disease and increases the risk of death	86
Abstinence is associated with better outcome in patients with hepatocellular carcinoma	86
Targeting cyclin M4 as a new therapeutical approach to treat alcoholic liver disease	86
Antibody response to gut microbiome bacteria in human alcoholic liver disease	86
Hepatic transcriptional signature of alcohol on genes involved in canonical retinoid metabolism	85
Rilpivirine as an anti-inflammatory agent in non-alcoholic fatty liver disease: evidence from human hepatocytes, hepatic stellate cells and blood cells	85
Validation of a discrete event simulation model evaluating the cost-effectiveness of long-term albumin administration in real-world UK patients with recurrent ascites	84
Ultrasound predictors of hemodynamic TIPS dysfunction: friends or foes?	84
IFI16 expression and its genotype variant are associated with NAFLD progression	84
Baveno VII algorithm can avoid endoscopic surveillance in patients with cirrhosis	84
Effect of housing temperature on non-alcoholic fatty liver disease development in C57BL/6N mice	84
Opposite correlations between hepatic β-oxidation activity and triglyceride levels in male and female rats after a high-fat diet supplemented with liquid fructose	83
Evaluation of genetic risk score of a dysmetabolic and obese population of southern Italy	83
Administration of Lactulose, Rifaximin, or combination therapy for hepatic encephalopathy is associated with a reduction in gastrointestinal cancers	83
Characterizing the histologic implications of resmetirom-induced liver volume reduction using artificial intelligence-powered digital pathology	83
Selective modulation of mitochondrial complex I ameliorates steatosis and hepatic inflammation in MCD-diet fed rats	82
Preclinical efficacy and clinical translatability of resmetirom in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH	82
Oral antibiotic treatment protects mice against the development of diet-induced non-alcoholic fatty liver disease but not against diet-induced intestinal barrier dysfunction	82
The effects of a structured dietetics intervention in patients with non-alcoholic fatty liver disease	80
A guinea pig model of pediatric non-alcoholic steatohepatitis	80
Molecular insights into the tumour suppressor role of Protein Phosphatase 2A B56 delta complex in human liver, and its clinically relevant inhibition by cancerous inhibitor of PP2A	80
Non-invasive tests of liver injury, inflammation and fibrosis are improved by efruxifermin and correlate with histological improvements in F2-F3 NASH patients: secondary analysis of Ph2b HARMONY study	80
A novel immunophenotyping of hepatocellular carcinoma based on amplified and mutated neoantigens for mRNA vaccine development	80
Semaglutide has beneficial effects on non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice	80
Carvedilol is associated with superior hemodynamic response and rebleeding rates in comparison to propranolol in secondary prophylaxis of variceal bleeding	79
Identification of new dominant neoantigens in hepatocellular carcinoma based on a single plasmid system with co-expressing patient’s HLA and antigen	79
SAFE score yielded a better performance than FIB-4 and NFS in predicting significant fibrosis among Asian NAFLD patients	77
High-risk Thrombophilia predict early thrombosis recurrence in acute non-cirrhotic portal vein thrombosis related to local factors: LOCAPORT	77
The pan-PPAR agonist lanifibranor decreases portal pressure in models of both hepatic and prehepatic portal hypertension	77
Monoacylglycerol lipase inhibition specifically in macrophages compromises liver regeneration by inducing interferon type 1 that negatively impacts on hepatocyte proliferation	76
The uptake of extracellular lipids promotes cholangiocarcinoma progression	76
Establishment and validation of a diagnostic model for liver inflammation in chronic hepatitis B (CHB) patients concurrent with non-alcoholic fatty liver disease (NAFLD) based on machine learning (ML)	76
Dynamic organotypic culture of primary liver cancer as a personalised immunocompetent drug screening platform for immuno-oncology	76
Bacterial infections in cirrhosis are associated with reduction in gut microbial phage-bacterial interactions	76
A systematic review and meta-analysis of the prevalence and cross-sectional severity of South Asian patients with non-alcoholic fatty liver disease	75
Ribosomal protein encoding genes: potential drivers of primary sclerosing cholangitis associated cholangiocarcinoma	75
Biological differences between clinically different muscle wasting phenotypes in patients with decompensated ESLD undergoing assessment for liver transplantation: a UK prospective cohort UK study	75
Critical investigation on the usability of hepatoma cell lines HepG2 und Huh7 as models for the metabolic representation of resectable hepatocellular carcinoma	74
Neurological dysfunction is improved after faecal microbiota transplantation in rats with bile duct ligated-induced chronic liver disease	74
Single cell RNAsequencing derived signature of hepatocyte de-differentiation predicts development of hepatocellular carcinoma in patients with liver cirrhosis	74
miR34a-5p is a target of E2F2 transcription factor in MAFLD-related HCC	74
Real-world treatment of decompensated liver cirrhosis in Italy: a propensity score-matched analysis of long-term versus acute albumin therapy	74
Nutritional therapy improves minimal hepatic encephalopathy in cirrhosis by improvement in sarcopenia, proinflammatory cytokines and myostatin: a double blind randomized controlled trial	74
Radiomic model based on contrast-enhanced CT imaging to predict early recurrence for patients with hepatocellular carcinoma after radical resection	73
Development of a target engagement biomarker for HSD17B13: preclinical pharmacodynamic studies of small molecule inhibition of HSD17B13 by INI-822	73

Effects of nutritional therapy on Sarcopenia in patient with liver cirrhosis-a randomised controlled trial	73
Targeting Apolipoprotein J restores autophagy and improves metabolic-associated fatty liver disease and diabetic nephropathy	73
TNFR1 inhibition reduces lipogenesis and improves insulin resistance and fibrosis in NAFLD	71
Temporal trajectory of the model for end-stage liver disease (MELD) score for prediction of mortality among patients with liver cirrhosis	71
Association between liver cirrhosis and cardiovascular events in a large German cohort-a population based study	70
Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)	70
Peroxisome proliferator-activated receptor alpha and estrogen related receptor alpha ligand combinations ameliorate non-alcoholic fatty liver disease	70
Primary cilia in biliary regeneration-a potential approach to improve outcomes in liver transplantation	69
NFATc1 drives progressive liver inflammation and fibrosis by regulating pro-apoptotic stress responses	69
Human antigen R (HuR) is a master regulator of hepatic glucose metabolism	69
Vitamin D deficiency associates with gut dysbiosis, endotoxemia and the risk of infectious complications in patients with liver cirrhosis	69
Goals of care and end-of-life for patients with advanced liver disease followed by a specialized palliative care clinic	69
Development and external validation of a model to predict multi-drug resistant bacterial infections in patients with cirrhosis	69
Magnesium modulation by CNNM4 silencing in DIAMOND mice via GalNAc-siRNA therapy: a new and effective therapeutic approach against MAFLD	68
The PNPLA3 I148M variant aggravates inflammation through dysfunctional LXR and PPAR gamma signalling in macrophages	68
Statins regulate PNPLA3 through a mechanism that requires SREBF2 in human liver cells	67
The prevalence and prognostic impact of myosteatosis with and without sarcopenia and its association with age and severity of liver cirrhosis	67
Circadian sleep-wake rhythms in non-alcoholic fatty liver disease	67
A heterozygous N559Y mutation in Semaphorin 7A promotes non-alcoholic fatty liver disease progression through induction of hepatic ROS production and inflammation	67
A novel HIF2A mutation causes dyslipidemia and promotes hepatic lipid accumulation	67
Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks	66
Experiences from a palliative care clinic specialized in liver diseases-utilisation, clinical characteristics of patients and outcomes	66
Booster SARS-CoV-2 vaccination elicits robust antibody response to wild type but not Omicron subvariants BA.4/5 in patients with cirrhosis	66
Liver nutrition clinic improves nutritional outcomes in patients with advanced cirrhosis	66
24-Hour urinary creatinine excretion (UCE) a marker of muscle mass is associated with mortality in critically ill patients with cirrhosis	65
Combined hepatic and adipose tissue transcriptomics highlights circulating NASH biomarkers	64
Liver transplantation for patients with fibrolamellar hepatocellular carcinoma: a comprehensive multicenter analysis to support future decision making	64
Increasing gut microbiota produced secondary bile acids to protect against non-alcoholic steatohepatitis	62
A new nuclear-erythroid-2-related factor 2 activator for the treatment of non-alcoholic steatohepatitis: evidence of metabolic and anti-fibroinflammatory effects in human precision cut liver slices	62
Biomarkers of endothelial dysfunction in patients with non-alcoholic fatty liver disease (NAFLD)	62
The prognostic role of lysophosphatidylcholines and their immunomodulatory potential in acute liver failure	62
A preferable signature of gut microbiota and bile acids predicted better outcomes of unresectable hepatocellular carcinoma to immune checkpoint inhibitors	62
Modeling ischemic cholangiopathy in human cholangiocyte organoid for screening of novel cholangio-protective agents	62
A novel imaging approach to investigate hepatitis E virus entry	60
Phenotypic characteristics of primary liver cancer in a large French cohort of patients with viral chronic liver disease followed-up before and after viral eradication: an ANRS study	60
The inhibition of the epigenetic efectors DNMT1 and G9a as a potential therapeutic strategy against the non-alcoholic fatty liver development	60
Low hemoglobin level predicts early hospital readmission in patients with cirrhosis and acute decompensation	60
Add-on benefits of AFP-L3, PIVKA-II and GALAD score to ultrasound plus AFP for surveillance of hepatocellular carcinoma	59
Sarcopenia assessed via computed tomography is associated with short-term outcomes and improves prognostic scores’ performance in critically ill patients with acute on chronic liver failure	59
Improvement of hepatic and extrahepatic functions and anti-inflammatory effects of nitazoxanide in disease models of LPS-induced systemic inflammation and acute-on-chronic liver failure	58
Combination of CCL4-induced decompensated cirrhosis with acute polymicrobial peritonitis as an optimized experimental model mimicking extrahepatic organ failures defined in ACLF	58
The efficacy of direct-acting antivirals for chronic hepatitis C in patients with the active oncological disease	58
Transversal psoas muscle thickness measurement is associated with response and survival in patients with hepatocellular carcinoma undergoing immunotherapy	58
Beta-blockers can reduce mortality in patients with acute-on-chronic liver failure-a multi-center study	58
Demonstration of gut-barrier dysfunction and endotoxemia in patients with cirrhosis presenting with acute variceal bleeding: a proof of concept	57
The regulatory protein and gene expression profile of skeletal muscle in chronic liver disease patients	57
Effect of liver stiffness on hepatocellular carcinoma phenotype in a biometric 3D model	57
Exacerbated response to patterned injury in the cirrhotic liver: potential susceptibility to ischemia	57
Ascites reduction and anti-inflammatory effects after albumin infusion for the management of cirrhosis: evidence from an animal model	57
Altered metabolic program initiates immune activation leading to hepatitis B surface antigen seroconversion in mild and severe hepatitis B reactivation patients	57
Poster Presentation - Table of Contents	57
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma	56
Survival of patients with advanced hepatocellular carcinoma treated with sorafenib in France during 2009–2018: analysis of the French hospital and claim database	56
Disclosures: commercial relationships	56
In vitro and in vivo preclinical efficacy of PD-L1-targeted liposomal doxorubicin as a combined therapy for the treatment of hepatocellular carcinoma	55
Incidence of hepatocellular carcinoma reduced in chronic hepatitis B patients treated with entercavir plus Biejia-Ruangan: extended follow-up of a multicenter, randomised, double-blinded, placebo-cont	55
HBsAg kinetics at month 9 after analogue treatment discontinuation in chronic hepatitis B eAg (-) predicts long-term HBV control	55
Transarterial radioembolisation in non resectable hepatocellular carcinoma in curative strategies: a single centre experience	55
Epigenetic modulation by DNA methyltransferase inhibition may enhance the effect of immune checkpoint inhibitors to restore HBV-specific T cell responses	55
Identification of resistance-associated variants after sofosbuvir treatment in chronic hepatitis E patients	55
Exploration of the lack of systematic surveillance for hepatocellular carcinoma for patients with non-alcoholic fatty liver disease	54
Impact of obesity on outcome of hepatocellular carcinoma in an Asian cohort: when should we consider obesity treatment?	54
Feasibility of a home-based, virtually-delivered, group exercise intervention in older patients with liver cancer (TELEX-Liver Cancer)	54
Impact of endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy	54
Prophylactic vaccine against hepatitis D virus (HDV) superinfection	54
Clinical course of biopsy-controlled alcohol-related liver disease	54
Combination of systemic immune-inflammation index and albumin-bilirubin score predict prognosis of sequential therapy with sorafenib and regorafenib in unresectable hepatocellular carcinoma	53
Risk factors for hepatic encephalopathy in hepatocellular carcinoma after sorafenib or lenvatinib treatment: a real-world study	53
Hepatitis B pre-genomic RNA level has a prospective supporting role for predicting the outcomes of the hepatitis B virus inactive carrier phase	52
Serum villin-1 level-a tell-tale sign of gut barrier failure in patients with cirrhosis and acute decompensation	52
Association of gut microbiome with prospective risk of hepatocellular carcinoma in chronic hepatitis B patients: a prospective nested case-control study	52
Drug screening for hepatocellular carcinoma: automating and miniaturizing organoid assays for drug screening	52
Management of severe, steroid-resistant and steroid-refractory hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy	52
Exogenous fibroblast growth factor 7 improved hepatocyte regeneration and ameliorated CCl4-induced acute liver injury in vivo	51
Lactobacillus protects against leaky gut, future decompensation, and hepatic encephalopathy in patients with cirrhosis	51
Remodeling of myeloid cells during hepatocellular carcinoma driven by beta-catenin activation	51
Place of steroids and prognosis factors for grade = 3 immune-checkpoint inhibitors induced hepatitis: a 6-year prospective study	51
HDV full genome sequencing and sensitive HBV genotyping from a large cohort of HBV/HDV co-infected patients	50
Impact of oral semaglutide on liver pathology and glucose metabolism in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus	50
Development of physiologically based pharmacokinetic model to predict liver exposure of SRT-015, a next-generation inhibitor of apoptosis signal-regulating kinase 1	50
Online education significantly improved gastroenterologists’ knowledge of the diagnostic and monitoring techniques used in liver fibrosis	50
The effect of standard of care lifestyle advice by a hepatologist in a routine clinical practice on steatosis and fibrosis development among NAFLD patients	50
The influence of probiotics on biologic and imagistic alterations in non-alcoholic steato-hepatitis	50
A PKA-associated liver-tissue rheostat curbs T cell receptor signalling and effector function of virus-specific CD8 T cells in chronic viral hepatitis	50
Semaglutide improves non-alcoholic steatohepatitis: a 10-year retrospective study	50
Validation of cut-off values proposed by the society of radiologists in ultrasound liver elastography for diagnosis of compensated advanced chronic liver disease using 2D shear wave elastography	49
Healthcare resource use and costs among patients with primary sclerosing cholangitis in Sweden-a retrospective population-based cohort study	49
Safety and signal intensity of a novel liver-specific MRI contrast agent, Orviglance® (manganese chloride tetrahydrate), in adult subjects with mild, moderate, or severe hepatic impairment	49
Effectiveness of vaccine education on vaccine awareness and vaccine uptake in patients with cirrhosis of liver of a tertiary care center in South India	49
Multiple vitamin co-exposure and mortality risk in metabolic dysfunction-associated fatty liver disease	49
Comparison of efficacy between liraglutide and phentermine/topiramate in obese patients with non-alcoholic fatty liver disease	49
Dynamics of liver stiffness measurements provide incremental prognostic information in advanced chronic liver disease	49
An explainable artificial intelligence model for prediction of high-risk non-alcoholic steatohepatitis	49
Socio-economic disparities drive the prevalence of non-alcoholic Fatty Liver Disease (NAFLD) among teenagers in the United States	48
Carbohydrate restriction inhibits tumor progression in a hepatocellular carcinoma mouse model	48